Cite
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
MLA
Forde, P. M., et al. “Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.” New England Journal of Medicine, vol. 386, no. 21, May 2022, pp. 1973–85. EBSCOhost, https://doi.org/10.1056/NEJMoa2202170.
APA
Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., Kerr, K., Wang, C., Ciuleanu, T.-E., Saylors, G. B., Tanaka, F., Ito, H., Chen, K.-N., Liberman, M., Vokes, E. E., & Taube, J. M. (2022). Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. New England Journal of Medicine, 386(21), 1973–1985. https://doi.org/10.1056/NEJMoa2202170
Chicago
Forde, P. M., J. Spicer, S. Lu, M. Provencio, T. Mitsudomi, M. M. Awad, E. Felip, et al. 2022. “Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.” New England Journal of Medicine 386 (21): 1973–85. doi:10.1056/NEJMoa2202170.